Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL326516 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL14379766 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL41472 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12758160 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL18537396 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3954927 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL379651 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2801580-B1 | Nucleoside phosphoramidate prodrugs | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | claimed |
| EP-4176266-A2 | EXOSOMAL TUMOR BIOMARKERS AND COLLECTIONS THEREOF | Cornell University (US) | 2023-05-10 | — | — | EP | claimed |
| CN-115397407-A | Novel therapeutic use of pleuromutilin compounds | 纳布里瓦治疗有限责任公司 | 2022-11-25 | — | — | CN | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1668022-A1 | PROCESS FOR PREPARING ANTIVIRAL NUCLEOSIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-14 | — | — | EP | claimed |
| US-6930093-B2 | Use of ribofuranose derivatives against inflammatory bowel diseases | VALEANT RESEARCH & DEVELOPMENT (US) | 2005-08-16 | — | — | US | claimed |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | ICN PHARMACEUTICALS SWITZERLAND LTD. | 2005-07-14 | — | — | US | claimed |
| US-20050080252-A1 | Process for preparing antiviral nucleoside derivatives | ROCHE PALO ALTO LLC | 2005-04-14 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| CN-1420723-A | Compositions and methods of L-nucleosides, L-nucleotides, and analogs thereof | ICN PHARMACEUTICALS (US) | 2003-05-28 | — | — | CN | claimed |
| EP-1132393-B1 | L-Ribavirin and uses thereof | ICN PHARMACEUTICALS (US) | 2003-04-09 | — | — | EP | claimed |
| EP-1244356-A4 | COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS | ICN PHARMACEUTICALS (US) | 2003-03-19 | — | — | EP | claimed |
| EP-1244356-A1 | COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS | ICN Pharmaceuticals, Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| EP-1132393-A1 | L-Ribavirin and uses thereof | ICN Pharmaceuticals, Inc. (US) | 2001-09-12 | — | — | EP | claimed |
| WO-2001045509-A1 | COMPOSITIONS AND METHODS FOR L-NUCLEOSIDES, L-NUCLEOTIDES, AND THEIR ANALOGS | ICN PHARMACEUTICALS, INC. (US) | 2001-06-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885ALDH1A1 2112/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885ALDH1A1 4371/4885 |
| US-20050080252-A1 | Process for preparing antiviral nucleoside derivatives | UMPS, ADAR, DUT | LMNA 1624/4885SMN1; SMN2 1881/4885ALDH1A1 1575/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885ALDH1A1 4371/4885 |
| US-20050153908-A1 | Use of ribofuranose derivatives against inflammatory bowel diseases | RNASE1, ATIC, SI | LMNA 1557/4885SMN1; SMN2 1606/4885ALDH1A1 881/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885ALDH1A1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.